MBX Biosciences
Logotype for MBX Biosciences Inc

MBX Biosciences (MBX) investor relations material

MBX Biosciences Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for MBX Biosciences Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

MBX 4291 obesity program

  • Q4 unblinding of the phase I/IIa C1 cohort is the key near-term milestone; planned readouts cover 12-week weight loss and its trajectory, longitudinal GI tolerability, and PK.

  • C1 includes 30 subjects: 20 on active treatment and 10 on placebo; the expected PK profile includes a 26-day T-half Cmax, supporting once-monthly dosing.

  • Competitive 12-week weight-loss benchmark is 6%-8%, based on phase III data for tirzepatide and semaglutide; May’s blinded B1 data showed 7% aggregate weight lowering in six active and two placebo subjects.

  • May’s blinded B1 safety dataset showed one mild diarrhea case; the prodrug design targets a gradual 5-6-day rise to Cmax to potentially improve GI tolerability.

  • Phase IIb is planned for next year, assuming success, with multiple doses and schedules informed by the unblinded study; management expects the study’s totality of evidence to support moving into phase II.

Obesity portfolio and strategy

  • C2 started after C1 and is expected to inform phase II design; additional data flow and development plans were expected to be discussed later in Q4.

  • Management is working toward a commercially competitive single-injection device for a future phase III; vial and syringe are planned for phase IIb to avoid delaying its start.

  • Strategy is to demonstrate differentiation through phase I/IIa and phase IIb data, then seek a partner to support concurrent, multiple phase III studies.

  • MBX 6180 triple G preclinical data in non-human primates supported projection of a monthly dose; two other obesity assets are in IND-enabling studies, with potential future candidate nominations.

  • The platform is designed to engineer peptide release profiles from one hour to 1,000 hours; management cited a wide-open landscape for true once-monthly agents.

Canvuparatide and commercial plans

  • Twelve-month open-label extension data showed sustained clinical benefit for chronic hypoparathyroidism; phase III oPTimize recruitment remains on track for completion in H2 next year.

  • Patient and investigator engagement has been strong, with no observed impact from YORVIPATH on recruitment or timelines; the weekly administration drew interest.

  • Management plans to build a U.S. commercial organization and has begun pre-commercial work; it views the chronic hypoparathyroidism market as suitable for standalone commercialization.

  • YORVIPATH’s reported Q3 revenue run rate was ~$1.2 billion, with estimated market penetration of 5%-7%; management cited this as validation of unmet need and market potential.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next MBX Biosciences earnings date

Logotype for MBX Biosciences Inc
Q4 202612 Mar, 2027
MBX Biosciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next MBX Biosciences earnings date

Logotype for MBX Biosciences Inc
Q4 202612 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

MBX Biosciences Inc. is a U.S.-based biotechnology company focused on developing precision medicines for endocrine disorders. The company’s research and development efforts target rare hormonal conditions, with a focus on creating peptide therapies that improve patient outcomes. Leveraging proprietary technology, MBX Biosciences aims to design therapies that address specific needs in endocrinology, including disorders related to hormone deficiencies or imbalances. The company advances its drug candidates through preclinical and clinical stages, seeking to bring effective treatments to patients with unmet medical needs. The company is headquartered in Carmel, Indiana, and its shares are listed on the NASDAQ.